After chemotherapy, a Whipple procedure, SBRT, and more chemotherapy, Robert Glazier is staying informed about treatment options for pancreatic cancer.
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.